Insight
Amol Akhade across-2
Amol Akhade/hiranandanihospital.org

Amol Akhade: Avutometinib + Defactinib in Recurrent LGSOC

Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X about a recent study by Susana N. Banerjee et al. published in JCO:

“New JCO Study: ENGOT-OV60/RAMP 201

Avutometinib (MEK1/2 inh) + Defactinib (FAK inh) in recurrent LGSOC

Dual MAPK + FAK blockade = tumor + stroma suppression

Efficacy:

  • ORR 31% overall
  • 44% in KRAS-mut vs 17% WT
  • PFS: 22.0 mo (KRAS-mut), 12.8 mo (WT)
  • DOR: 31.1 mo

KRAS-mutant tumors = MAPK addicted = better MEK+FAK response

Responses even post-MEKi!”

Title: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal: JCO

Authors: Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O’Malley, Toon Van Gorp, Rachel N. Grisham

Read the full article.

Amol Akhade

More posts featuring Amol Akhade on OncoDaily.

Alessandro D. Santin Amol Akhade Ana Oaknin Andrew Clamp avutometinib Bradley J. Monk cancer Carol Aghajanian Charlie Gourley Christine Gennigens David M. O'Malley defactinib Els Van Nieuwenhuysen Emily Prendergast ENGOT-OV60/RAMP 201 Erin Salinas Gregg Newman Hagop Youssoufian Hye Sook Chon JCO Kari Ring Kathleen N. Moore KRAS-mutant tumors LGSOC Low-Grade Serous Ovarian Cancer Manuel Rodrigues Nicoletta Colombo OncoDaily Oncology Premal H. Thaker Rachel N. Grisham Robert W. Holloway Stephanie Lustgarten Susana N. Banerjee Suyog Cancer Clinics Toon Van Gorp Véronique D’Hondt